



Patent
Attorney's Docket No. 003300-891

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

JOHN-OLOV JANSSON et al.

Application No.: 10/030,429

Filed: March 22, 2002

For: USE OF INTERLEUKIN-6 IN
TREATMENT OF OBESITY
AND/OR OBESITY ASSOCIATED
DISORDERS

)
)
)
)
)
)
)
)
)

Group Art Unit: 1642

Examiner: (unassigned)

RECEIVED
APR 24 2002
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56,
Applicants hereby submit the following information in conformance with 37 C.F.R.
§§ 1.97 and 1.98.

It is contemplated that this submission be read in conjunction with the Information
Disclosure Statement that was previously filed on January 10, 2002.

Three (3) articles from the technical literature are provided.

For the convenience of the Examiner a form PTO-1449 is attached. It is requested
that an Examiner-initialed copy of this form be returned to the undersigned once these items
are considered.

Information Disclosure Statement
Application No. 10/030,429
Attorney's Docket No. 003300-891
Page 2

The examination and allowance of the Application are respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Benton S. Duffett, Jr.
Benton S. Duffett, Jr.
Registration No. 22,030

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: April 22, 2002



Substitute for form 1449A/PTO APR 22 2002 U.S. PATENT AND TRADEMARK OFFICE	ATTORNEY'S DKT NO. 003300-891	APPLICATION NO. 10/030,429
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT John-Olov JANSSON <i>et al.</i>	
	FILING DATE April 22, 2002	GROUP 1642

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231)